Increased carboplatin concentration in liver tumors through temporary flow retardation with starch microspheres (Spherex) and gelatin powder (Gelfoam): An experimental study in liver tumor-bearing rabbits

被引:25
作者
Pohlen, U
Berger, G
Binnenhei, M
Reszka, R
Buhr, HJ
机构
[1] Free Univ Berlin, Univ Hosp Benjamin Franklin, Dept Surg, D-12200 Berlin, Germany
[2] Max Delbruck Inst Mol Med, Berlin, Germany
关键词
chemotherapy; chemoembolization; carboplatin; gelatin powder; starch microspheres;
D O I
10.1006/jsre.2000.5856
中图分类号
R61 [外科手术学];
学科分类号
摘要
Regional chemotherapy of primary and secondary malignant liver tumors is superior to systemic therapy. The regional advantage can be further increased by flow retardation. Absorbable gelatin powder (Gelfoam) and starch microspheres (Spherex) may serve as embolizing agents because of their particle size and embolization time. Carboplatin was for the first time applied as a cytostatic agent in regional chemotherapy. Embolization and flow retardation times were measured. The embolization time of Gelfoam was 27 min, and that of starch microspheres (Spherex), 7 min, on average. Mean flow retardation of Gelfoam was 153 min, and that of starch microspheres (Spherex) 38 min. The concentration differences in systemic and regional chemotherapy were determined in VX-2 liver tumor-bearing rabbits. In regional chemotherapy, the tumor concentration was increased by a factor of 3.6 compared with systemic therapy. Coapplication with an embolizing agent increased the tumor concentration of carboplatin by a factor of 44 to 47. Concentrations of absorbable gelatin powder (Gelfoam) and starch microspheres (Spherex) did not differ significantly. (C) 2000 Academic Press.
引用
收藏
页码:165 / 170
页数:6
相关论文
共 46 条
[1]   REGIONAL DELIVERY OF MICROSPHERES TO LIVER METASTASES - THE EFFECTS OF PARTICLE-SIZE AND CONCENTRATION ON INTRAHEPATIC DISTRIBUTION [J].
ANDERSON, JH ;
ANGERSON, WJ ;
WILLMOTT, N ;
KERR, DJ ;
MCARDLE, CS ;
COOKE, TG .
BRITISH JOURNAL OF CANCER, 1991, 64 (06) :1031-1034
[2]  
[Anonymous], NEOPLASMS LIVER, DOI DOI 10.1007/978-4-431-68349-0_1
[3]  
ASKLEN LA, 1991, INVAS METAST, V11, P58
[4]  
ATIQ OT, 1992, CANCER, V69, P920, DOI 10.1002/1097-0142(19920215)69:4<920::AID-CNCR2820690414>3.0.CO
[5]  
2-Y
[6]  
Benita S, 1984, J Microencapsul, V1, P317, DOI 10.3109/02652048409031544
[7]  
BLANCHARD RJ, 1965, P SOC EXP BIOL MED, V118, P465
[8]  
BREEDIS C, 1954, AM J PATHOL, V30, P969
[9]  
CARTER R, 1991, BRIT J SURG, V78, P757
[10]  
CIVALLERI D, 1991, CANCER, V68, P988, DOI 10.1002/1097-0142(19910901)68:5<988::AID-CNCR2820680513>3.0.CO